Boehringer brings early data for GLP-1 receptor showing almost 15% weight loss after 46 weeks
Boehringer Ingelheim and Zealand Pharma released Phase II data on their weight loss candidate, a glucagon and GLP-1 receptor agonist called …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
